PapersFlow Research Brief
Acute Lymphoblastic Leukemia research
Research Guide
What is Acute Lymphoblastic Leukemia research?
Acute Lymphoblastic Leukemia research is the study of epidemiology, genetic basis, treatment strategies, and outcomes of childhood acute lymphoblastic leukemia (ALL), including genetic alterations, minimal residual disease, pharmacogenomics, prognostic factors, and relapse risk.
This field encompasses 66,062 published works on pediatric oncology topics such as childhood cancer, acute lymphoblastic leukemia, and treatment outcomes. Research addresses challenges in minimal residual disease detection and pharmacogenomics for thiopurine therapy. Growth data over the past five years is not available.
Topic Hierarchy
Research Sub-Topics
Genetic Alterations in Childhood ALL
Researchers investigate recurrent mutations, chromosomal translocations, and gene fusions driving pediatric acute lymphoblastic leukemia pathogenesis. This includes genomic profiling and their roles in leukemogenesis.
Minimal Residual Disease in ALL
Studies focus on detection methods like flow cytometry and PCR for measuring treatment response and predicting relapse in childhood ALL patients. Research optimizes monitoring protocols and risk stratification.
Pharmacogenomics of Thiopurine Therapy
This area examines genetic variants influencing thiopurine metabolism, toxicity, and efficacy in ALL treatment regimens. Researchers develop dosing algorithms based on TPMT and NUDT15 polymorphisms.
Prognostic Factors in Pediatric ALL
Investigates clinical, biological, and treatment-related predictors of outcome, including age, white cell count, and immunophenotype. Studies validate and refine prognostic models for therapy allocation.
Relapse Risk and Salvage Therapy in ALL
Focuses on mechanisms of resistance, patterns of relapse sites, and novel salvage regimens including CAR-T cells and blinatumomab. Research addresses early marrow vs. extramedullary relapse management.
Why It Matters
Acute Lymphoblastic Leukemia research directly impacts pediatric oncology by improving treatment outcomes and addressing relapse risks in children. Grupp et al. (2013) demonstrated clinical activity of chimeric antigen receptor-modified T cells targeting CD19 in two children with relapsed/refractory ALL, achieving complete remission. This approach shows promise for patients failing standard chemotherapy, as detailed in "Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia" (2013). Such advancements reduce reliance on intensive therapies and inform survivorship care, connecting to findings in "Chronic Health Conditions in Adult Survivors of Childhood Cancer" (2006) by Oeffinger et al., which reported high rates of chronic health conditions in survivors.
Reading Guide
Where to Start
"Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia" by Grupp et al. (2013), as it provides a concrete clinical example of an emerging ALL treatment with direct evidence of remission in relapsed pediatric cases.
Key Papers Explained
"Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia" (Grupp et al., 2013) establishes CAR-T cell efficacy in ALL, building on classification frameworks in "WHO classification of haematolymphoid tumours" (Bell et al., 2010) and "World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues" (Harris et al., 1999), which define diagnostic criteria. Oeffinger et al. (2006) in "Chronic Health Conditions in Adult Survivors of Childhood Cancer" extends this by quantifying long-term effects, informing survivorship after therapies like those in Grupp et al.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research continues to emphasize genetic alterations, minimal residual disease, and pharmacogenomics for relapse prevention, with no recent preprints or news available to indicate shifts.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | CBTRUS Statistical Report: Primary Brain and Central Nervous S... | 2013 | Neuro-Oncology | 12.1K | ✓ |
| 2 | Cancer treatment and survivorship statistics, 2016 | 2016 | CA A Cancer Journal fo... | 6.1K | ✓ |
| 3 | Cancer Statistics, 2006 | 2006 | CA A Cancer Journal fo... | 5.3K | ✓ |
| 4 | WHO classification of haematolymphoid tumours | 2010 | Radiopaedia.org | 3.8K | ✓ |
| 5 | Chronic Health Conditions in Adult Survivors of Childhood Cancer | 2006 | New England Journal of... | 3.5K | ✕ |
| 6 | Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid ... | 2013 | New England Journal of... | 3.4K | ✓ |
| 7 | Diagnosis and management of acute myeloid leukemia in adults: ... | 2009 | Blood | 3.4K | ✓ |
| 8 | World Health Organization Classification of Neoplastic Disease... | 1999 | Journal of Clinical On... | 3.3K | ✕ |
| 9 | Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-AB... | 2001 | Science | 3.1K | ✕ |
| 10 | ABT-199, a potent and selective BCL-2 inhibitor, achieves anti... | 2013 | Nature Medicine | 2.9K | ✕ |
Frequently Asked Questions
What treatments have shown activity in relapsed acute lymphoblastic leukemia?
Chimeric antigen receptor-modified T cells with specificity for CD19 achieved complete remission in two children with relapsed/refractory B-cell ALL. Grupp et al. (2013) reported this in "Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia." The therapy demonstrated clinical activity after standard treatments failed.
How is acute lymphoblastic leukemia classified?
The WHO classification of haematolymphoid tumours provides a framework for ALL within haematolymphoid neoplasms. Bell et al. (2010) outlined this in "WHO classification of haematolymphoid tumours." It integrates morphology, genetics, and clinical features for diagnosis.
What chronic health issues affect childhood cancer survivors?
Adult survivors of childhood cancer, including those with ALL, experience high rates of chronic health conditions. Oeffinger et al. (2006) found this in a study published as "Chronic Health Conditions in Adult Survivors of Childhood Cancer." These conditions arise from cancer treatments and require long-term monitoring.
What defines treatment outcomes in leukemia research?
Treatment outcomes in ALL research focus on response assessment, survival, and relapse risk. The field covers prognostic factors and minimal residual disease, as seen across 66,062 works. Papers like those on pharmacogenomics evaluate thiopurine therapy efficacy.
How does pharmacogenomics apply to ALL treatment?
Pharmacogenomics in ALL research examines genetic influences on drug response, particularly for thiopurine therapy. It identifies prognostic factors tied to treatment outcomes and relapse risk. This approach refines personalized therapy in pediatric oncology.
What role does minimal residual disease play in ALL?
Minimal residual disease assessment predicts relapse risk and guides treatment intensity in childhood ALL. Research integrates it with genetic alterations for prognosis. It remains central to evaluating therapy success in pediatric cases.
Open Research Questions
- ? How can chimeric antigen receptor T-cell therapies be optimized to prevent relapse in ALL patients post-remission?
- ? What genetic alterations most accurately predict minimal residual disease persistence in childhood ALL?
- ? Which pharmacogenomic markers best forecast thiopurine therapy response and toxicity in pediatric ALL?
- ? How do chronic health conditions in ALL survivors vary by treatment exposure and age at diagnosis?
- ? What prognostic factors most reliably stratify relapse risk across diverse ALL subtypes?
Recent Trends
The field maintains focus on genetic alterations, minimal residual disease, pharmacogenomics, prognostic factors, thiopurine therapy, and relapse risk, with 66,062 total works but no five-year growth data specified.
No recent preprints or news coverage from the last 12 months or six months alters these priorities.
Research Acute Lymphoblastic Leukemia research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Acute Lymphoblastic Leukemia research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers